SEC Form 4 · accession 0001127602-18-010694
BIOCRYST PHARMACEUTICALS INC · BCRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Yarlagadda S Babu
Officer — Senior VP - Drug Discovery
Period of report
Mar 6, 2018
Accepted (ET)
Mar 8, 2018 · 3:48 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882796
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 6, 2018 | M | 20,622 | $3.26 | A | 120,618 | D | |
| Common StockF1 | Mar 6, 2018 | F | 15,223 | $5.18 | D | 105,395 | D | |
| Common Stock | Mar 6, 2018 | M | 9,378 | $3.26 | A | 114,773 | D | |
| Common StockF2 | Mar 6, 2018 | F | 5,902 | $5.18 | D | 108,871 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option | $3.26 | Mar 6, 2018 | M | 20,622 | D | Mar 14, 2009 | Mar 14, 2018 | Common Stock | 20,622 | 0 | D |
| Emp. Stock Option (Right to Buy) | $3.26 | Mar 6, 2018 | M | 9,378 | D | Mar 14, 2009 | Mar 14, 2018 | Common Stock | 9,378 | 0 | D |
Explanation of responses
- F1Shares of Common Stock delivered to the Company to satisfy payment of exercise price and tax withholding in connection with stock option exercise.
- F2Shares of Common Stock delivered to the Company to satisfy payment of exercise price in connection with stock option exercise.